Valeant Pharmaceuticals Intl Inc (VRX) announces redemption of $445.0 Million of 6.875% Senior Notes Due 2018
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) announced the redemption of $445.0 Million of 6.875% Senior Notes Due in 2018. After the transaction, the company will have approximately $500.0 million outstanding of the 6.875% Senior Notes Due 2018.
Move comes under Newly Authorized Securities Repurchase Program
On November 20th, Valeant announced that its Board of Directors had authorized a new securities repurchase program which will commence on November 21st, 2014. The program which commenced on November 21, 2014 allowed for the repurchase of senior notes, common shares, and/or other securities. The repurchase program replaced a previous program under which the company made no purchases of securities.
Major Shareholder recently purchased nearly $30 million in shares
ValueAct Capital, headed by Jeff Ubben, recently reported increasing its position in Valeant. The fund acquired 210,000 shares at a price of $142.25/share. This implies a purchase of nearly $30 million. ValueAct now owns 19.13 million shares of the company. ValueAct Capital is a value investing based fund, with a long term philosophy.
Latest posts by Steve Vrionis (see all)
- Buffett on What Risks Could Take Down: Berkshire Hathaway Inc. - May 12, 2017 07:26 AM PST
- Why the AIG Ruling Is No Drag for Federal National Mortgage Association(OTCMKTS:FNMA) & Federal Home Loan Mortgage Corp(OTCMKTS:FMCC) Investors - May 10, 2017 09:09 AM PST
- Amazon.com, Inc.(NASDAQ:AMZN): Warren Buffett said you shouldn’t have missed this Jeff Bezos Interview - May 9, 2017 08:29 AM PST